Assembly Biosciences (ASMB) Raised to “Buy” at BidaskClub

BidaskClub upgraded shares of Assembly Biosciences (NASDAQ:ASMB) from a hold rating to a buy rating in a research report report published on Tuesday morning.

Other analysts also recently issued reports about the stock. Zacks Investment Research upgraded shares of Assembly Biosciences from a hold rating to a buy rating and set a $37.00 target price on the stock in a report on Wednesday, November 15th. Jefferies Group initiated coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They issued a buy rating and a $50.00 target price on the stock. B. Riley initiated coverage on shares of Assembly Biosciences in a report on Friday, January 5th. They issued a neutral rating and a $35.00 target price on the stock. Finally, ValuEngine downgraded shares of Assembly Biosciences from a hold rating to a sell rating in a report on Thursday, December 7th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. The company has a consensus rating of Buy and an average price target of $39.25.

Shares of Assembly Biosciences (ASMB) opened at $46.57 on Tuesday. Assembly Biosciences has a fifty-two week low of $18.60 and a fifty-two week high of $52.37.

Assembly Biosciences (NASDAQ:ASMB) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.17. The business had revenue of $2.66 million during the quarter, compared to the consensus estimate of $1.25 million. sell-side analysts predict that Assembly Biosciences will post -3.22 earnings per share for the current fiscal year.

In other news, Director William R. Ringo sold 1,000 shares of Assembly Biosciences stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $49.37, for a total value of $49,370.00. Following the transaction, the director now directly owns 20,465 shares of the company’s stock, valued at $1,010,357.05. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Over the last three months, insiders sold 3,000 shares of company stock worth $141,270. 19.60% of the stock is currently owned by insiders.

Institutional investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors purchased a new position in shares of Assembly Biosciences in the second quarter worth approximately $161,000. Parametric Portfolio Associates LLC increased its position in shares of Assembly Biosciences by 13.6% in the second quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 1,203 shares in the last quarter. Legal & General Group Plc purchased a new position in shares of Assembly Biosciences in the second quarter worth approximately $212,000. Wells Fargo & Company MN purchased a new position in shares of Assembly Biosciences in the second quarter worth approximately $213,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Assembly Biosciences by 15,448.6% in the second quarter. The Manufacturers Life Insurance Company now owns 11,195 shares of the biopharmaceutical company’s stock worth $232,000 after acquiring an additional 11,123 shares in the last quarter. 61.31% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Assembly Biosciences (ASMB) Raised to “Buy” at BidaskClub” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://www.com-unik.info/2018/02/03/assembly-biosciences-asmb-raised-to-buy-at-bidaskclub.html.

About Assembly Biosciences

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Receive News & Ratings for Assembly Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Assembly Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit